Prime Nordic

Prime Nordic Prime Nordic plc is an investment company placing investments and holding a portfolio of Nordic comp

Prime Nordic plc's mission is to provide sustainability through creating long-term and social value by investing in well governed companies that contribute positively to society. Prime Nordic seeks sound governance, risk management and compliance structures within their investee companies, as well as promoting healthy social, environmental and economic systems.

From the entire team at Prime Nordic, wishing you a Merry Christmas and a prosperous New Year.
24/12/2020

From the entire team at Prime Nordic, wishing you a Merry Christmas and a prosperous New Year.

MEDTECH INNOVATIONS IN THE NORDICSAn award winning innovative helmet technology, detecting cancer from breath, self-lumi...
18/12/2020

MEDTECH INNOVATIONS IN THE NORDICS

An award winning innovative helmet technology, detecting cancer from breath, self-luminous cancer tissue and hospital health monitoring. There are many examples of recent medtech progress in the Nordic region, writes Malin Otmani for Nordic Life Science News.

The original article can be found at: https://nordiclifescience.org/medtech/

Sweden:
Innovative helmet technology receives the Polhem Prize

Three of the founders of MIPS (Multi-directional Impact Protection System) have been awarded the Polhem Prize

Since it was founded, MIPS has focused on brain protection systems within helmet-based safety. Now three of its founders, Peter Halldin, Hans von Holst, and Svein Kleiven, have been awarded the 2019 Swedish Engineers’ Polhem Prize. The prize is Sweden’s oldest, founded in 1876 in memory of the inventor Christopher Polhem, and it is also one of the most prestigious technical awards. Each year it honors high-level technological innovation or for an ingenious solution to a technical problem.

The three founders of MIPS received the award for their MIPS Brain Protection System, which is designed to reduce rotational motion that may be transferred to the brain upon angled impacts to the head.“Our ambition has always been to reduce the risk of brain damage for helmet users worldwide. We believe that protection against rotational motion in helmets should be as obvious as having seat belts in cars,” says Peter Halldin, Chief Science Officer, MIPS. The company was grown out of the realization by brain surgeon Hans von Holst during the 1990s that a lot of his patients got brain injuries despite the fact that they had worn a helmet. He started collaborating with Peter Halldin at the Department of Neuronik at the Royal Institute of Technology (KTH) and they concluded that rotational motions may affect the brain and increase the risk of brain damages. Together with Svein Kleiven, von Holst started developing a computational model of the human brain, used for measuring the effects of the MIPS solution and rotational motions.“A helmet equipped with the MIPS solution enables a relative movement between the head and the helmet and takes into account impacts from all angles. In this way, we mimic the brain’s own protection system and thereby reduce the risk of both minor and more severe brain injuries,” says Hans von Holst, brain surgeon and professor, KTH.

Finland:
A new device for early diagnosis of gastric cancer

A new cancer screening device, developed by European researchers including VTT Technical Research Centre of Finland, detects cancer from breath testing.

The new device, called SniffPhone, is currently in a prototype phase, but the developers state that it enables early diagnosis of gastric cancer from a person’s exhaled breath. The small sensor device can be attached to a smartphone, and in practice, the user holds the device in front of his or her mouth and exhales onto the sensor to give a breath sample. The device measures the contained Volatile Organic Compounds (VOCs) using highly sensitive nanotechnology-based chemical sensors. The measurements are sent via Bluetooth, using a smartphone, to a dedicated cloud platform where they are analyzed by the appropriate medical personnel.

“Commercialization of the device is planned to take place through a spin-off company.”

The SniffPhone project is part of the EU’s Horizon 2020 Funding Programme and consists of nine partners: Technion – Israel Institute of Technology, NanoVation, Cellix, microfluidic ChipShop, University of Latvia, University of Innsbruck, Siemens, JLM Innovation and VTT.
Within the project prototypes have been developed and validated, for example by means of clinical studies, and the next step is finding financiers. Commercialization of the device is planned to take place through a spin-off company.

Denmark:
Self-luminous tissue facilitates tumor operations

A new technology developed by researchers at Rigshospitalet in Copenhagen, makes cancer tissue luminescent, and hence helps surgeons to detect and remove diseased tissue.

Today, normal white light is used during operations. During a cancer operation the surgeon needs to remove both the cancer tumor and also the diseased tissue that surrounds the tumor in order to assure that the patient will not have a relapse after the surgery. In normal light it is hard to see the diseased tissue and therefore it may be difficult be sure that all that is harmful has been removed.

“In normal light it is hard to see the diseased tissue and therefore it may be difficult be sure that all that is harmful has been removed.”

“Usually today it is hard to see where cancer tissue begins and where it ends. Therefore one usually removes the tumour and additional centimeters of tissue around it. In the bowel a couple of extra centimeters does not necessarily cause any harm, but extra centimeters in the brain means a risk of affecting important functions, such as the language centre. Methods used today mean a significant risk for relapse, since all of the sick tissue might not be removed,” says Andreas Kjær, professor at the University of Copenhagen and chief physician at Rigshospitalet, and also one of the researchers behind the new technology.

The new technology has been developed within the project Fluoguide, initiated by a collaboration with Rigshospitalet, the University of Copenhagen and the company Fluoguide A/S. In the new technology a compound is injected into the blood and illuminates certain tissues during the surgery. The compound contains a fluorophore that binds to cancer cells expressing uPAR. The uPAR binding is mediated by a targeting molecule. Fluoguide’s targeting molecules bind rapidly to cancer cells but quickly disappear from the systemic circulation. Thus, the surgeon can see the uPAR expressing cancer already 30 minutes after injection. The first indication for FG001 is glioblastoma but FG001 has potential in several indications.

“Treatment of glioblastoma is in great need of improvement. The Fluoguide technology seems interesting and potential improvements in the treatment are very welcome, even though one single product won’t take us all the way on its own,” says Magnus Tisell, chief physician, Sahlgrenska University Hospital, Sweden.

Norway:
New hospital health-monitoring announced as Cool Idea winner

Moon Labs was announced the winner of the very first Protolabs European Cool Idea Award.

The company received the award for its health-monitoring system for hospital patients. The prize money will be used to further develop its small, wireless and cost effective system that provides continuous health information about patients. The company’s system, EVO, monitors the vital parameters of hospital patients and warns if their conditions worsen, and hence require immediate treatment.

“The company has produced its system using its own 3D print technology.”

The system consists of three parts; a small biosensor for disposable use that is attached behind the patient’s ear and continuously monitors heart and breathing frequency, as well as oxygenation over a period of up to five days, a gateway that transfers information to the patient’s electronic journal, and software that enables doctors and hospital staff to follow their patients’ vital parameters and calculate and discover potential health problems as early as possible. The company has produced its system using its own 3D print technology.

Protolab’s European Cool Idea Award will annually award up to 1.25 million SEK, distributed over four quarters, in the form of production services at Protolabs. The aim is to help innovators produce prototypes and initiate a first production batch.

Moon Labs system will now be tested at three Norwegian hospitals and the company hopes to receive CE marking and start producing larger volumes at the beginning of 2021.

Financing 0 Comment 576 Views Senzime raises proceeds of approximately SEK 100 million Malin Otmani December 4, 2020 Senzime has successfully completed a directed issue of 4,545,000 shares, at a subscription price of SEK 22 per share, raising proceeds of approximately SEK 100 million. A number of Sw...

Nordic countries are in the leading positions in continuing to work towards a sustainable futureThe implications of the ...
16/12/2020

Nordic countries are in the leading positions in continuing to work towards a sustainable future

The implications of the current global pandemic encompass public health, economics, social stability, politics, and geopolitics. This crisis is unprecedented in severity at least since the influenza epidemic at the end of World War I, and still very uncertain in its trajectory. The world could change markedly. However, if we take the right approach to crisis management, we may learn important positive lessons for the future.

The UN published the Sustainable Development Report, based on performance of all member countries on 17 August 2020.

Click here for the full rankings - https://dashboards.sdgindex.org/rankings

Sweden leads in the way of sustainable living.

Despite the pandemic, the Nordic countries continue to rank amongst the worlds leaders when it comes to meeting the sustainable development goals. Sweden led every country and achieved the first place in leading the way towards a more sustainable future according to the SDG Index, which follows up on the Sustainable Development Goals in the UN’s 2030 Agenda. Denmark is only a few points behind in second, with Finland 3rd on the list, while Norway made their way to the 6th spot.

Explore Results

Explore the global data from the Sustainable Development Report 2020 through their interactive map - https://dashboards.sdgindex.org/map

About the Sustainable Development Report 2020

The Sustainable Development Report 2020 presents the SDG Index and Dashboards for all UN member states and frames the implementation of the Sustainable Development Goals (SDGs) in terms of six broad transformations. It was prepared by teams of independent experts at the Sustainable Development Solutions Network (SDSN) and the Bertelsmann Stiftung.

Bertelsmann Stiftung

The Bertelsmann Stiftung is one of the largest foundations in Germany. It works to promote social inclusion and is committed to advancing this goal through programs that improve education, shape democracy, advance society, promote health, vitalise culture and strengthen economies. The Bertelsmann Stiftung is a non-partisan, private operating foundation.

Sustainable Development Solutions Network

The Sustainable Development Solutions Network (SDSN) has been operating since 2012 under the auspices of the UN Secretary-General. SDSN mobilises global scientific and technological expertise to promote practical solutions for sustainable development, including the implementation of the Sustainable Development Goals (SDGs) and the Paris Climate Agreement.

The full Sustainable Development Report is available here - https://dashboards.sdgindex.org/downloads

The Nordics have, according to recent studies, outperformed their global peers in business performance metrics during th...
16/12/2020

The Nordics have, according to recent studies, outperformed their global peers in business performance metrics during the Covid-19 crisis. The Nordics have proved resilient in the face of the pandemic when it comes to business performance, with all countries in the region bar Norway, showing better TSR (total shareholder returns) averages than global statistics. Leading the results are Denmark which has drastically outperformed its global peers, with Finland and Sweden also more resilient than the global average.

Global Overview -The performance in the first phase of the COVID-19 crisis has been industry-driven

Before we undertake an examination of how the Nordic countries have each responded to the crisis, it is prudent to assess the response of the global markets as means of a comparison.

The overall global performance in the first phase of the COVID-19 crisis has largely been industry-driven. Since the initial crash in March, stock market performances worldwide, at least in some jurisdictions, have recovered well, at least temporarily. Even so, volatility may continue given unknowns in disease progression, the likelihood of a vaccine, and governments’ commitment to launching subsequent social and economic measures. While at the aggregate level, we see stock prices returning toward pre-crisis levels, a more granular view reveals divergent trajectories among industries (see pic 1). At the positive end of the spectrum, Healthcare is thriving, with companies on average delivering 11% returns globally since early January. Technology, Media and Telecom (TMT) has also offered positive returns, but there have been significant disparities among its sub-sectors. Technology, for instance, has experienced a surging demand and maintained a positive outlook, whereas media companies have had to cope with both lower advertisement revenues and a rapid shift to in-home media consumption.

Aside from Healthcare and TMT, the remaining industries under analysis have all shown negative returns since the onset of the COVID-19 crisis. Consumer companies have already seen a small decrease in value creation, driven by a predictably declining demand for travel and luxury products. We also see a decrease in value creation in Industrial Goods (IG) companies, even though the full extent of COVID’s financial impact has thus far been limited to certain sub-sectors, mainly automotive, transportation, and logistics. This apparent discrepancy between TSR performance and financial performance has likely been driven by an underlying and common expectation of a longer-term economic slowdown, which would inevitably impact IG companies across the board. Finally, at the most heavily impacted end of the spectrum, Energy has experienced an 11% reduction in returns, the result of COVID-19’s exacerbation of an already unsteady and volatile pre-crisis global oil market.

Performance Among Nordic Companies

The above-outlined industry patterns raise two critical questions at the Nordic level: how resilient have Nordic companies been, and how has the effectiveness of their responses compared to global industry peers? To account for global industry patterns and differences in industry mix, we can observe the relative TSR performance of each industry within each Nordic nation and compare it to the average of their global peers. The weighted results according to each industry’s market capitalisation can be viewed below (see pic). The results show that Nordic companies have fared well, on average demonstrating greater returns than their global peers. There are some commonalities among the Nordic nations’ performances, despite some different approaches to combatting the crisis: the consumer segment, for instance, has maintained a positive TSR in all four countries, and TMT has thrived in Denmark, Finland, and Sweden.

We can see that Denmark has drastically outperformed its peers, both in the Nordic countries and globally. Finland and Sweden have also been more resilient than the global average, however, Norwegian companies, by contrast, have suffered the most, with a higher loss of comparative value.

Denmark has outperformed its global peers by more than 10pp. Across industries, it has seen a consistent over- or on par performance, with the only exception being Energy. The positive delta to other Nordic countries is primarily explained by above-average returns from Industrial Goods, which in the other Nordics are largely aligned with their global industry peers.

Swedish and Finnish companies have also outperformed their global peers on the whole. Notably, between the two, Finland trails behind Sweden in all segments except TMT. Compared to global averages within both TMT and Energy, Sweden and Finland have experienced returns well in excess of their peers, whereas within Industrial Goods, both nations have performed close to peer level. Sweden’s consumer companies represent a notable outlier, outperforming the global average by about 11pp. This seems to be driven by Sweden’s online industries, particularly online retail services and entertainment.

Finally, Norway has been the hardest hit Nordic nation. This is at least partially caused by Norway’s susceptibility to certain secondary effects of the crisis, notably the extreme fluctuations in oil prices and the weakening of the Norwegian krone, both of which have raised investor concerns. In fact, only within the consumer segment has Norway outperformed global peers, though even here it remains below the other Nordics, likely as a result of the challenges to Norway’s significant seafood industry.

Conclusion
We are now 6 months into a global pandemic and the Nordic Countries can look back on a successful strategy and experience of how they have each handled the crisis, although with different nuances and outcomes. There have been several promising vaccine trials conducted with the Swedish/British company AstraZeneca leading one of them. The Nordic Health Care Sector has also proved to be well adept to cope with a pandemic, operating at a far from full capacity throughout the worst period. In addition to the vaccine trials, there are several other Covid-19 treatments that have showed effectiveness and are now are being trialled giving comfort to the Health Care Sector.

The infrastructure of the Nordic schooling systems is also very advanced and has enabled all four countries in the region to deliver on-line teaching and on-line exams without downtime, with Swedish primary schools and nurseries never in lock down or closed. Overall, the Nordic approach throughout the pandemic has been to get the entire society involved, leaning on and trusting industry experts rather than governmental or political intervention. In Denmark for instance it was the teacher unions that have made up the plans on how to re-open up the schools, not the government.

The overall feeling has been one of optimism within the Nordic Region, and with such displays of strength and resilience, many investors have turned to the Nordic Markets with confidence.

Despite these unprecedented and unusual times, the Nordic markets have continued to remain resilient and stable compared to their global peers. Prime Nordic believes that by applying overall diversification, not only to the sectors of the companies in which it invests, but also to their geographic locations throughout the Nordic region, contributes & supports the continued growth and success of the Prime Nordic portfolio.

For a more in-depth analysis of top performers during the previous financial crisis, including case studies and a five-step approach to success, please refer to the *BCG paper Crisis Can Spark Transformation and Renewal

* BCG - Boston Consulting Group

SEE FULL POST HERE:

The Nordics have, according to recent studies, outperformed their global peers in business performance metrics during the Covid-19 crisis. The Nordics have proved resilient in the face of the pandemic when it comes to business performance, with all countries in the region bar Norway, showing better....

The global pandemic has created shock-waves & large-scale disruptions to the global economy as a whole, however througho...
16/12/2020

The global pandemic has created shock-waves & large-scale disruptions to the global economy as a whole, however throughout these uncertain times, the Nasdaq Nordics have shown remarkable resilience, with the Nasdaq Nordic First North 25 (FN25) printing all time highs in the midst of the crisis.

Prime Nordic examines and looks to emulate the performance of the FN25 Index. Over the last 12 months the Prime Nordic Portfolio has actually surpassed the performance of the index, however we continue to look at the index as the leading indicator of Nordic market health.

The FN25 consists of the largest and most traded shares listed on the Nasdaq First North Growth Market. Companies included in the FN25 are selected through a two-step process as follows:

The 30 largest companies measured by market capitalisation are selected.

The 25 most traded shares within this pool, measured by aggregated trading turnover over a six-month period, are selected for the index.

The FN25 is reviewed semi-annually in January and July.

Since inception in October 2015 the index has produced a mean average annual growth of 56.63%.

Covid Response

The FN25 initially reacted with the global sentiment of the crisis with a short term sell off. In March 2020, the market momentarily retraced to the prices of December 2018, however a swift reversal at this support level soon saw confidence return to the market with the index exceeding it's all time highs as soon as mid May 2020. Thereafter the market has continued to print further highs, with the price currently approaching 4000.

Although past performance is no guarantee of future results, and granting that the market may well present a further correction at some point, few markets across the world have demonstrated such resilience and recovery to the Covid-19 crisis as the FN25. Moving forward Prime Nordic is confident that the Nordic marketplace will continue to offer further such opportunities of robust, sustainable investments.

SEE FULL POST HERE:

The Nordic marketplace response to Covid-19

Prime Nordic plc is delighted to announce an investment into the Swedish Biopharmaceutical Company, Genovis.  Based at t...
16/12/2020

Prime Nordic plc is delighted to announce an investment into the Swedish Biopharmaceutical Company, Genovis. Based at the esteemed Medicon Village, the life science research park in Lund, Genovis provides unique enzymes and technologies for analytical characterisation and conjugation of biopharmaceuticals.

About Genovis

Genovis was founded in 1999 by Sarah Fredriksson where she acted as the CEO until May 2015 after which she went on to be chairman of the board. Initially, the business mainly focused on nanoparticles (NIMT®) intended for both the preclinical and clinical markets. Beginning around 2010, the company launched advanced unique enzymes for analysis of biological drugs, and antibodies particularly for therapeutic use. The enzyme portfolio grew and more enzymes in various formats have been added since then. In 2015 Genovis streamlined its operations to specialise in development, production and sales of enzymes for the growing global pharmaceutical industry that works on developing biologicals for the future.

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

Overarching Goals

Genovis will increase knowledge about biological processes that enable new and effective treatments and medicines.
Genovis will establish its products as the solution of choice in all analyses, from early discovery to production of tomorrow’s medications.
Genovis will create long-term shareholder value through results that generate both dividends for shareholders and funding for the continued innovative development of the Company.
Operational Strategy

Offer innovation combined with high quality through internal development by working close to the frontlines of research and by nurturing relationships with prestigious research groups, as well as by actively seeking new technologies through the acquisition of intellectual property or companies.
Genovis will work closely with customers to implement the enzymes in analysis procedures from drug discovery, through clinical trials to production control of the customer's drug candidate throughout its lifetime.
Genovis will be an innovative company and an attractive workplace that takes advantage of staff expertise and offers all employees the opportunity to influence their work situation and professional development.
With co-shareholders including Avanza Pension, Nordnet Pension, Handelsbanken & Goldman Sachs, Prime Nordic is proud to become an investor into a company providing a positive impact to the development of biopharmaceuticals, alongside a clear and driven potential for capital growth.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Growth Market under the ticker GENO, and Erik Penser Bank is the Company’s Certified Adviser.

Strategy, Investment, Partnering & Commercialisation for Life Science Executive LeadersFor 6 years, the LSX World Congre...
16/12/2020

Strategy, Investment, Partnering & Commercialisation for Life Science Executive Leaders

For 6 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal making and commercialisation.

LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life science giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

Prime Nordic's Alex Upton & Scott Flook attended the conference and were delighted to meet up with Ulf Hannelius, CEO of Diamyd Medical, a Prime Nordic investee company, alongside Anna Styrud, the company's CFO. Diamyd is a First-in-class antigen-specific immuno-therapeutic under development for the preservation of endogenous insulin production. The topic of conversation centered around the results of recent clinical trials which have shown very successful and exciting outcomes. These results provide a boost to patients with Autoimmune Diabetes (Type 1 & LADA), representing 10-20% of all diabetes patients, and a multibillion US dollar addressable market.

Also in attendance at the Congress were industry giants such as Nasdaq, Goldman Sach's, Lilly & Medtronic, as well as a host of life science and healthcare companies, many of which falling within the scope of the Prime Nordic investment criteria. Prime Nordic gained valuable insights into the progression and potential of these companies, presenting strong & interesting cases for investment.

For more information please visit the LSX World Congress website:
https://www.lsxleaders.com/lsx-world-congress

Address

Aviation House, 125 Kingsway, Holborn
London
WC2B6NH

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Telephone

+442039230470

Alerts

Be the first to know and let us send you an email when Prime Nordic posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Prime Nordic:

Share